VKAs and DOACs with Pall T Onundarson: The Never-Ending Comparison
Pall T Onundarson, Professor Emeritus at Landspitali University Hospital, shared a thoughtful paragraph on LinkedIn:
”’You will be assassinated by industry’ a prominent professor in England in the field of coagulation told me after I presented the Fiix test and the results of the Fiix-trial in 2014.
I thought he was being funny at the time but he wasn´t. I don´t laugh anymore.
Our group has published three clinical studies (Onundarson PT et al, The Lancet Haematology 2015; Oskarsdottir AR et al, Blood 2021; Ingason AB et al., Blood VTH 2025) that all demonstrate more improvement in oral anticoagulation (OAC) outcomes by far (about 50% reduction in thromboembolism without increase in bleeding) with Fiix-monitored warfarin than has been observed with any other OAC compared to well managed conventional PT-INR monitored warfarin. Off note, also more effective than DOAC drugs with similar major bleeding incidence.
Short conclusion: Warfarin should not be monitored with the PT-INR and we have used the Fiix normalized ratio since 2016.
For sure I remain alive 11 years later – but these studies are hardly ever mentioned in anticoagulation discussions. In psychology it is called “cognitive dissonance” ( or “Don´t confuse me with facts, I´ve made up my mind”).
The publications are hardly ever cited by scientists studying anticoagulants, talkin at conventions and writing clinical guidelines.
Guidelines that are supposed to assure patients and society that patients receive the best possible care. As if the studies don´t exist. And we all know now that many patients still need warfarin and VKAs. Don´t we at least owe it to them to improve their anticoagulation outcomes if possible?
Was the renowned professor in England correct? It seems like the “assassination” is not literal but presents as purposeful “silencing” or “cancellation” by my medical collegues in the field.
Does industry come into play as the professor suggested? I don´t know but is it possible that the drug industry influences the medical profession and in particular key opinion leaders through payments of all kinds to such a degree that prestigious leaders in the field are willing to ignore a new method?
A new method that possibly could save more lives and prevent more disability than all the current recommended treatments – and save an enormous amount of money at the same time? Is there bias?
I can understand that some scepticism would exist – but wouldn´t the appropriate path be to independently test whether the theory has merits and if the published results can be independently confirmed?
The figure compares the results of the three clinical studies mentioned above. Click on it to enlarge.
P.s.: The dilute Fiix test can be used to measure DOAC drugs as well as warfarin (Letertre LR et al, J Thromb Haemostasis 2016).”
The Never-Ending Comparison of effectiveness of use of VKAs or DOACs and mnitoring of those drugs is discussed for some time now.
Read Pall T Onundarson sharing his views on the perspectives!

Stay informed on the emerging in the field of coagulation disorders with Hemostasis Today.
-
Apr 13, 2026, 05:43Wolfgang Miesbach: A Historic Experiment That Changed Our Understanding of ITP
-
Apr 13, 2026, 04:49Danielle Boyle: This Consultation Is an Opportunity for The Entire ITP Community to Be Heard
-
Apr 13, 2026, 04:18Stephen Cornelissen: You Might Be Eligible to Donate Blood – Here’s Why It’s Worth Checking
-
Apr 13, 2026, 04:12Angie Read: A Powerful Conversation on Survival, Recovery, and Purpose on Stroke Sisters’ Latest Episode
-
Apr 13, 2026, 04:04Ramy Abdelnaby: Telestroke Rounds Show Superior Guideline Adherence in Subacute Care
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings